KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KalVista Pharmaceuticals (NASDAQ: KALV) announced the granting of inducement stock options to two newly-hired employees. The compensation committee approved options to purchase a total of 14,000 shares of KalVista common stock on March 3, 2025.
The options' exercise price equals the closing price of KalVista stock on the grant date. The vesting schedule includes 25% after one year, with the remaining vesting monthly over three years, contingent on continued employment. The options have a 10-year term and fall under KalVista's Inducement Equity Incentive Plan, complying with Nasdaq Listing Rule 5635(c)(4).
KalVista Pharmaceuticals (NASDAQ: KALV) ha annunciato l'assegnazione di opzioni su azioni come incentivo a due nuovi dipendenti. Il comitato per la retribuzione ha approvato opzioni per l'acquisto di un totale di 14.000 azioni ordinarie di KalVista il 3 marzo 2025.
Il prezzo di esercizio delle opzioni corrisponde al prezzo di chiusura delle azioni KalVista alla data di concessione. Il piano di maturazione prevede il 25% dopo un anno, con il restante che matura mensilmente per tre anni, a condizione di continuare l'impiego. Le opzioni hanno un termine di 10 anni e rientrano nel Piano di Incentivazione Azionaria per Induzione di KalVista, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
KalVista Pharmaceuticals (NASDAQ: KALV) anunció la concesión de opciones sobre acciones como incentivo a dos nuevos empleados. El comité de compensación aprobó opciones para comprar un total de 14,000 acciones ordinarias de KalVista el 3 de marzo de 2025.
El precio de ejercicio de las opciones es igual al precio de cierre de las acciones de KalVista en la fecha de concesión. El calendario de adquisición incluye el 25% después de un año, con el resto adquiriéndose mensualmente durante tres años, condicionado a la continuidad del empleo. Las opciones tienen un plazo de 10 años y están bajo el Plan de Incentivos de Capital por Inducción de KalVista, cumpliendo con la Regla de Cotización Nasdaq 5635(c)(4).
KalVista Pharmaceuticals (NASDAQ: KALV)는 두 명의 신입 직원에게 유인 주식 옵션을 부여했다고 발표했습니다. 보상 위원회는 2025년 3월 3일에 KalVista 보통주 14,000주를 구매할 수 있는 옵션을 승인했습니다.
옵션의 행사 가격은 부여일의 KalVista 주식 종가와 동일합니다. 권리 행사 일정은 1년 후 25%, 나머지는 3년 동안 매월 발생하며, 지속적인 고용을 조건으로 합니다. 이 옵션은 10년 기한을 가지며, KalVista의 유인 자본 인센티브 계획에 따라 Nasdaq 상장 규칙 5635(c)(4)에 부합합니다.
KalVista Pharmaceuticals (NASDAQ: KALV) a annoncé l'octroi d'options sur actions d'incitation à deux nouveaux employés. Le comité de rémunération a approuvé des options pour l'achat d'un total de 14 000 actions ordinaires de KalVista le 3 mars 2025.
Le prix d'exercice des options est égal au prix de clôture des actions KalVista à la date d'octroi. Le calendrier d'acquisition comprend 25 % après un an, le reste étant acquis mensuellement sur trois ans, sous réserve de la poursuite de l'emploi. Les options ont une durée de 10 ans et relèvent du Plan d'Incitation en Actions de KalVista, conformément à la Règle de Cotation Nasdaq 5635(c)(4).
KalVista Pharmaceuticals (NASDAQ: KALV) hat die Gewährung von Anreiz-Aktienoptionen an zwei neu eingestellte Mitarbeiter bekannt gegeben. Der Vergütungsausschuss genehmigte Optionen zum Kauf von insgesamt 14.000 Aktien von KalVista am 3. März 2025.
Der Ausübungspreis der Optionen entspricht dem Schlusskurs der KalVista-Aktien am Gewährungsdatum. Der Vesting-Zeitplan umfasst 25 % nach einem Jahr, wobei der verbleibende Betrag monatlich über drei Jahre vestet, abhängig von der fortgesetzten Beschäftigung. Die Optionen haben eine Laufzeit von 10 Jahren und fallen unter den Anreiz-Aktienplan von KalVista, der den Nasdaq-Listing-Regel 5635(c)(4) entspricht.
- None.
- None.
One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject to the new employee’s continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of KalVista’s Inducement Equity Incentive Plan and a stock option agreement covering the grant.
The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc., is a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. Our lead investigational product is sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE). Sebetralstat is under regulatory review by the
For more information about KalVista, please visit www.kalvista.com or follow on social media at @KalVista and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250304423728/en/
KalVista Pharmaceuticals, Inc.
Media:
Jenn Snyder
Vice President, Corporate Affairs
(857) 356-0479
jennifer.snyder@kalvista.com
Investors:
Ryan Baker
Head, Investor Relations
(617) 771-5001
ryan.baker@kalvista.com
Source: KalVista Pharmaceuticals, Inc.
FAQ
How many shares are covered by the inducement options granted by KalVista Pharmaceuticals (KALV)?
What is the vesting schedule for KALV's March 2025 inducement stock options?
When do the KALV inducement stock options expire?
What is the exercise price for KALV's March 2025 inducement options?
